Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290388 · ClinicalTrials.gov registry record · Phase 1
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by 23andMe.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06290388 is a Phase 1 study that was terminated before completion, run by 23andMe. The registered enrollment target is 5 participants.
The verdict
NCT06290388, a Phase 1 study, was terminated before completion, sponsored by 23andMe.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies.
Interventions
- DRUG 23ME-01473
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2024-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06290388
The ClinicalTrials.gov registry entry for NCT06290388 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 23andMe, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 23ME-01473 is the first listed.
NCT06290388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06290388 about?
NCT06290388 is a clinical study titled "Study of 23ME-01473 in Patients With Advanced Solid Malignancies". This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard th...
What is the current status of trial NCT06290388?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2024-03-07. Estimated completion is 2024-11-10.
What interventions are being tested in trial NCT06290388?
The interventions under investigation include: 23ME-01473 (DRUG).
Who is sponsoring clinical trial NCT06290388?
This trial is sponsored by 23andMe, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.